Terns Pharmaceuticals, Inc. Net Current Asset Value

Net Current Asset Value of TERN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Current Asset Value growth rates and interactive chart.


Highlights and Quick Summary

  • Net Current Asset Value for the quarter ending March 31, 2022 was $146 Million (a -8.17% decrease compared to previous quarter)
  • Year-over-year quarterly Net Current Asset Value decreased by -18.89%
  • Annual Net Current Asset Value for 2021 was $159 Million (a 144.74% increase from previous year)
  • Annual Net Current Asset Value for 2020 was $65 Million (a 290.74% increase from previous year)
  • Annual Net Current Asset Value for 2019 was $16.6 Million (a -80.64% decrease from previous year)
Visit stockrow.com/TERN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Current Asset Value of Terns Pharmaceuticals, Inc.

Most recent Net Current Asset Valueof TERN including historical data for past 10 years.

Interactive Chart of Net Current Asset Value of Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc. Net Current Asset Value for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $146.16
2021 $159.16 $171.06 $180.2 $188.8 $159.16
2020 $65.03 $0.0 $0.0 $0.0 $65.03
2019 $16.64 $16.64
2018 $85.96

Business Profile of Terns Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.